Clinical trial
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59-adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed
NCT05422326 is registered in ClinicalTrials.gov with Seqirus as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59-adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed
- Lead sponsor
- Seqirus
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- July 18, 2022
- Completion date
- March 24, 2023
- Enrollment
- 260 (actual)
- Sites
- 18
Conditions
As the registry lists them; a condition with its own page is linked.